logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Cytochrome P450 3A Inhibitor class drugs

    FiltersReset Filters
    7 results

    • evotaz

      (atazanavir and cobicistat)
      E.R. Squibb & Sons, L.L.C.
      Usage: EVOTAZ® is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for adults and pediatric patients weighing at least 35 kg. Its use in treatment-experienced patients should be guided by baseline protease inhibitor resistance.

    • genvoya

      (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
      Gilead Sciences, Inc.
      Usage: GENVOYA is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥25 kg) with no prior antiretroviral treatment history or to replace an existing regimen in virologically-suppressed patients on a stable regimen for at least six months without treatment failures or resistance.

    • norvir

      (Ritonavir)
      AbbVie Inc.
      Usage: NORVIR is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in adults and pediatric patients.

    • paxlovid

      (nirmatrelvir and ritonavir)
      Pfizer Laboratories Div Pfizer Inc
      Usage: PAXLOVID is indicated for the treatment of mild-to-moderate COVID-19 in adults at high risk for severe disease progression, including hospitalization or death. It is not approved for COVID-19 prevention via pre-exposure or post-exposure prophylaxis.

    • prezcobix

      (DARUNAVIR ETHANOLATE and COBICISTAT)
      Janssen Products LP
      Usage: PREZCOBIX is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for both treatment-naïve and treatment-experienced adults and pediatric patients (weighing at least 40 kg) without specific darunavir resistance mutations.

    • stribild

      (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
      Gilead Sciences, Inc.
      Usage: STRIBILD® is indicated for treating HIV-1 in adults and pediatric patients aged 12 and older (weighing at least 35 kg) without prior antiretroviral treatment or to replace a stable regimen in those virologically suppressed for at least 6 months, without resistance to its components.

    • symtuza

      (Darunavir, Cobicistat, Emtricitabine, and Tenofovir alafenamide)
      Janssen Products LP
      Usage: SYMTUZA is indicated for treating HIV-1 infection in adults and pediatric patients (≥ 40 kg) with no prior antiretroviral therapy or who are virologically suppressed on a stable regimen for at least 6 months, with no known resistance substitutions.